Research Article
Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience
Table 4
Intervention modalities at different stages.
| | | 1st intervention () | 2nd intervention () | 3rd intervention () | 4th intervention () | 5th intervention () |
| | TACE | 17.40% | 35.20% | 44.20% | 53.80% | 53.80% | | TARE | 4.30% | 5.70% | 7% | 7.70% | 0.00% | | RFA | 16.20% | 13.6% | 11.60% | 3.80% | 0.00% | | PEI | 11.50% | 13.6% | 18.6% | 19.20% | 7.70% | | Resection | 3.80% | 2.30% | 0.00% | 0.00% | 0.00% | | Transplant | 1.30% | 13.6% | 11.60% | 0.00% | 7.70% | | Sorafenib | 8.50% | 2.30% | 7% | 0.00% | 23.10% | | Best supportive care | 37% | 13.60% | 0.00% | 15.40% | 7.70% |
|
|
TACE: transarterial chemoembolization; TARE: transarterial radioembolization; RFA: radiofrequency ablation; PEI: percutaneous ethanol injection.
|
